Could TRT or a GLP-1 be doing 90% of your results?

Here is the uncomfortable arithmetic at the center of almost every peptide success story: the peptide is rarely the only thing that changed. The person who swears BPC-157 healed their shoulder was also resting it. The one who credits a GH secretagogue for their leaner waist started a cut the same month. And an enormous share of the most dramatic "peptide transformations" are happening on top of testosterone replacement therapy or a GLP-1, two interventions with effect sizes so large that anything stacked beside them is, statistically, noise.

This is the confounder problem, and it is the single biggest reason honest attribution is hard. Before you give a peptide credit, you have to subtract the known commodity it's riding on. Usually, once you do, there isn't much left to explain.

What testosterone does on its own

We do not have to guess at testosterone's effect size. In a 1996 NEJM trial, healthy men given 600 mg of testosterone enanthate per week for 10 weeks gained fat-free mass and strength, and the group on testosterone without exercise still out-gained the group doing supervised resistance training on placebo. The testosterone-plus-exercise arm added 6.1 kg of fat-free mass in ten weeks (Bhasin, NEJM 1996). That was a supraphysiologic dose, but the direction is unambiguous: testosterone alone moves body composition more than training alone.

Clinical TRT is more measured, and honesty cuts both ways here. The Testosterone Trials. 790 men over 65 with low testosterone, treated for a year, found clear improvements in sexual function but only modest, mixed effects on walking distance and no significant benefit for vitality or fatigue (Snyder, NEJM 2016). So TRT is not magic for energy. But for the lean-mass, strength, libido, and "feel like themselves again" cluster that people most often attribute to their recovery or GH peptide, testosterone is a proven, well-characterized driver. On our scale that is an A on evidence. A peptide layered on top is being asked to produce a signal against that swing, and it almost never can.

What a GLP-1 does on its own

The GLP-1 story is even starker because the numbers are enormous. In STEP 1, the pivotal semaglutide trial, 1,961 adults lost a mean of 14.9% of body weight at 68 weeks versus 2.4% on placebo; more than half the treated group lost at least 15% (Wilding, NEJM 2021). Tirzepatide went further: in SURMOUNT-1, 2,539 adults lost up to 20.9% of body weight at 72 weeks versus 3.1% on placebo (Jastreboff, NEJM 2022). The full prescribing information for these drugs documents the same magnitude (Wegovy label, DailyMed).

Now picture someone running a "fat-loss peptide" while on tirzepatide. They drop two pant sizes, the metabolic peptide gets the testimonial, and the GLP-1 doing 90% of the work gets none of the credit. The peptide didn't lie. The math did.

The attribution rule

This is why every profile on this site carries a confound watch, and why our metabolic and recovery peptides hedge so hard. MOTS-c, for instance, is popular precisely with people already optimizing hard, training, GLP-1s, caloric control, so any metabolic improvement they report is entangled with much better-evidenced variables. Even tesamorelin, which is FDA-approved and actually has human RCTs behind its visceral-fat effect, is usually run alongside training, a GLP-1, or TRT, so individual users still can't isolate what it's doing for them.

The fix is not cynicism; it's sequencing and measurement. Attribute to the known commodity first. If you started or changed a TRT dose or a GLP-1 in the same window you added a peptide, the peptide gets no credit for that period, full stop. Those drugs have RCT-proven effects measured in hundreds of participants; your peptide has, at best, a handful of small human studies and, more often, animal data and anecdote. The effect-size asymmetry is so large that you can't run a clean n-of-1 while an anabolic or an incretin is also moving (n-of-1 methodology, PMC3972259). Add the placebo response, real, neurobiological, and concentrated exactly on the subjective outcomes peptides are sold against, and the unattributed peptide is fighting two enormous confounders at once.

The grounded takeaway

If you want to know what a peptide is actually doing, run it as the only thing that changed: a stable TRT dose held flat, no new GLP-1, one compound, one objective metric, long enough to clear the placebo wash-in. Anything less, and the most likely answer is the boring one. A lot of what gets sold as a peptide result is the testosterone, or it's the GLP-1, proven commodities doing proven work, with a more expensive, less-evidenced molecule taking the bow.